Ceci n’est pas Science  by Accili, Domenico
Cell Metabolism
CrosstalkCeci n’est pas ScienceDomenico Accili1,*
1Columbia University Medical Center and Berrie Diabetes Center, New York, NY 10032, USA
*Correspondence: da230@columbia.edu
http://dx.doi.org/10.1016/j.cmet.2015.03.011
Biomedical research is not immune to economic imperatives. But as the realities of profit encroach ever
closer on what was once regarded as an idealistic and selfless endeavor, the author reflects on four trends
that are hollowing out the research enterprise.Figure 1. Magritte, Rene´. La trahison des images (The Treachery of Images)
ª 2015 C. Herscovici/Artists Rights Society (ARS), New York.The ‘‘Ceci n’est pas.’’ series of paintings
by Rene´ Magritte have always stricken a
powerful cord in me through their ability
to lay bare, in simplest terms, the discon-
nect between appearance and reality,
form and substance.
For a biomedical investigator trying to
discover causes and design treatments
for disease, this is the best of times, and
the worst of times. As practitioners of
modern-day alchemy, it’s easy to become
intoxicated by the very promise of what’s
attainable today. The early days of my
career, when it took me three years to
find the mutation causing an extreme
form of diabetes in a patient, look quaint
by comparison with today, when anybody
with a high-speed internet connection
can accomplish as much in a matter of
seconds. Yet as I survey the worldwide
landscape of biomedical research in my
field of endeavor, I feel increasingly as if
I were in the Muse´e Magritte, staring at
things that aren’t what they appear to
be—and lacking in artistic value to boot.
These Are Not Funding Agencies
We are increasingly micromanaged by
funders in ways that thwart scientific in-
quiry. I’m not discussing the grants peer
review process. In fact, I am defending it
as the firewall that protects the intellectual
freedom of grantees from the whims
of funders. Funding bodies are in full
‘‘mission creep’’: from setting a lofty
vision to dictating mundane content,
cherry-picking what experiments they
like and what results deserve continuing
support. The romantic fallacy of such en-
gineering is too painfully obvious to bear
repeating: if we knew where or what to
look for, it wouldn’t be research. There
have always been committees trying to
forecast or direct science, but they now
hold the power of the purse to an unprec-
edented extent: to wit, the scramble thatensues any time a new ukase comes
out of a research institute director’s
office, anointing the new topic ‘‘du jour.’’
Dictating research goals stifles creativity,
promotes mediocrity, and fosters an
unhealthy relationship between grant ad-
ministrators and researchers. The lamen-
table trendwhereby the former vicariously
run research programs through targeted
research initiatives doesn’t benefit sci-
ence and doesn’t increase the pace of
discovery. At any given time, any topic
can be ripe for a ‘‘targeted’’ intervention,
but not all topics at all times.Venture Philanthropy Is an
Oxymoron
Patient advocacy and philanthropic
research organizations are essential to
bring about change in medicine. Unfortu-
nately, some of these organizations areCell Metabolismshedding their traditional philanthropic
model to embrace one that emphasizes
financial return on their grants, and views
the latter as a form of venture capital.
Increasingly, the idea is to provide grants
that don’t cover the costs of the proposed
research—owing to low overhead—but
make unreasonable demands on intellec-
tual property generated through the work
funded. This arrangement subverts the
very concept of philanthropic funding
and turns advocacy into a dubious busi-
ness model. I, for one, will neither apply
for nor accept a grant from any organiza-
tion that practices venture philanthropy.Pharma Is Not the Enemy
The difference between a great discovery
and making a drug is the same that
exists in politics between campaigning
and governing: they require different21, April 7, 2015 ª2015 Elsevier Inc. 503
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Crosstalkskillsets, and while some individuals are
gifted at both, excellence in one area
doesn’t portend excellence in the other.
I am reminded that in the U.S., the
successful implementation of visionary
‘‘liberal’’ social programs, like Social
Security and Medicare, hinged upon civil
servants that hardly fit the stereotype of
warm and fuzzy liberalism. Most dis-
coveries on which successful drugs are
based have come from academia, and
most successful drugs from industrial
development. Academic drug develop-
ment programs generally lack resources
and staying power to be truly transfor-
mative. On the other hand, industrial dis-
covery programs rarely see the light of
day, victims of the whims of shareholders,
byzantine regulatory paths, or commer-
cial necessities. Publication is often
neglected and thus rarely benefits the
common goal of increasing our knowl-
edge base to catalyze medical break-504 Cell Metabolism 21, April 7, 2015 ª2015throughs. I am not writing a defense of
the pharmaceutical industry; their lobby-
ists are legion and can speak for them-
selves. But the academic/industrial divide
that persists to this day is outdated, inim-
ical to biomedical progress, and rooted
in supine unawareness of what the other
side does and what strengths they have.
Academia Is Not Real Estate
Worldwide, academic life for an investi-
gator in the biomedical sciences con-
tinues to deteriorate in ways that are
not unlike what we have witnessed in
the manufacturing or service industries.
Academic medical centers were not
designed to be financed by research
grants, and yet have come to resemble a
real estate operation in which extracting
rent from hapless tenants takes prece-
dence over the mission of improving
people’s lives through research. I am
often told that universities ‘‘lose money’’Elsevier Inc.on research grants, and I have no doubt
that they do. But then how exactly is the
constant refrain of ‘‘getting more grants’’
going to solve the problem? Squeezing
researchers by monetizing their perfor-
mance strikes me as an ineffective
and ultimately self-defeating approach
to the long-term financial health of univer-
sity medical centers. Academic freedom,
already imperiled by the thinning stream
of funds, becomes a mockery when the
only metrics is indirect costs.
Although most of my career has been
spent in theU.S., and the tenor of these re-
flections has been inspired bymy daily ex-
periences here, these issues affect the
research community worldwide. It be-
hooves those of us who have been in this
line of work for a long time to speak force-
fully and act consequentially against
trends that are undermining the very foun-
dations of the research enterprise. Once
broken, it won’t be made easily whole.
